LogoLogo

NeurATRIS

Overview

NeurATRIS (Infrastructure de Recherche Translationnelle pour les Biothérapies en Neurosciences) is the French national translational research infrastructure for neuroscience, coordinated by CEA. Founded in 2012 under the Investissements d’Avenir programme, it is designed to accelerate the translation of basic neuroscience discoveries into medical innovations for neurological and neurodegenerative diseases. It is the French component of EATRIS-ERIC.

Member Nodes

NeurATRIS federates 6 research centres. CEA Paris-Saclay MIRCen provides preclinical primate models, AAV gene therapy, and PET imaging. CEA Paris-Saclay SHFJ covers radiopharmaceuticals, PET tracers, and pharmacokinetics. The Institut de Myologie / IHU-A-ICM covers neuromuscular disease and biotherapy. Pitié-Salpêtrière provides neuroimaging, clinical neurology, and Phase I/II trials.

Services Offered

NeurATRIS provides a one-stop access model for academic and industrial researchers:

Preclinical Services

  • Large animal models (NHP) for neurological disease are available at MIRCen.
  • Rodent pharmacology and behavioural models are provided across sites.
  • AAV and lentiviral vector production and quality control are offered at MIRCen.
  • In vivo preclinical PET and MRI are available at SHFJ and MIRCen.

Clinical Services

  • Phase I/II clinical trials in neurological diseases are conducted through the network.
  • Clinical neuroimaging (3T MRI, PET-MRI, MEG) is available at CENIR and Paris Brain Institute.
  • Pharmacokinetics and pharmacodynamics studies are supported by SHFJ.
  • Outcome measure development is led by NeuPEL at the Institut de Myologie.

Biotherapy and Gene Therapy

  • Cell therapy and gene therapy translational support are provided across NeurATRIS nodes.
  • AAV vector design through clinical-grade production is available at MIRCen.
  • iPSC derivation and neural differentiation are supported at multiple sites.

Connections

Resources

Graph View

Tags

Backlinks